Alaunos Therapeutics (NASDAQ:TCRT) Shares Cross Above 50 Day Moving Average – Here’s What Happened

Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) shares crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $1.65 and traded as high as $1.75. Alaunos Therapeutics shares last traded at $1.66, with a volume of 77,505 shares traded.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Zacks Research initiated coverage on shares of Alaunos Therapeutics in a research note on Tuesday, November 17th. They issued a “hold” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Alaunos Therapeutics in a report on Friday, November 13th. Finally, TD Cowen assumed coverage on shares of Alaunos Therapeutics in a research note on Friday, November 13th. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

View Our Latest Analysis on TCRT

Alaunos Therapeutics Stock Performance

The stock’s 50-day simple moving average is $1.65 and its 200 day simple moving average is $2.25. The company has a market capitalization of $6.99 million, a PE ratio of -0.87 and a beta of -1.02.

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.05) by $1.74. On average, analysts expect that Alaunos Therapeutics, Inc. will post -0.20 earnings per share for the current year.

Institutional Trading of Alaunos Therapeutics

An institutional investor recently bought a new stake in Alaunos Therapeutics stock. Integrated Wealth Concepts LLC purchased a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $44,000. Integrated Wealth Concepts LLC owned about 1.51% of Alaunos Therapeutics at the end of the most recent reporting period. 27.72% of the stock is owned by institutional investors.

Alaunos Therapeutics Company Profile

(Get Free Report)

Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.

Further Reading

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.